MBX Biosciences (MBX) Share-based Compensation (2023 - 2026)

MBX Biosciences has disclosed Share-based Compensation across 4 years of filings, most recently posting $5.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $5.5 million, up 198.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.2 million (up 144.55% YoY), and the FY2025 annual result was $8.7 million, up 66.16% from the prior year.
• Share-based Compensation came in at $5.5 million for Q1 2026 at MBX Biosciences, up from $2.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.5 million in Q1 2026 to a low of $227000.0 in Q3 2023.
• The 4-year median for Share-based Compensation is $1.3 million (2025), against an average of $1.6 million.
• Across the five-year window, Share-based Compensation advanced 13.31% in 2025 and jumped 198.21% in 2026, its largest moves.
• MBX Biosciences' Share-based Compensation stood at $1.0 million in 2023, then surged by 46.17% to $1.5 million in 2024, then jumped by 78.49% to $2.7 million in 2025, then jumped by 106.48% to $5.5 million in 2026.
• The last three Share-based Compensation figures came in at $5.5 million (Q1 2026), $2.7 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.